Shigenobu Ishida
Kurume University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shigenobu Ishida.
Epilepsia | 1998
Shigenobu Ishida; Yushiro Yamashita; Toyojiro Matsuishi; Masachika Ohshima; Hiroharu Ohshima; Hirohisa Kato; Hisao Maeda
Summary: Purpose: To describe the recent epidemic of photosensitive seizure that occurred in relation to an episode of the television animation program “Pocket Monsters,” we report four patients who experienced seizures while watching the episode in question. We also report some technical aspects of the program episode.
Epilepsia | 1998
Shigenobu Ishida; Houtetsu Shimamoto; Toshi Abe; Hiromichi Motooka; Seishi Sakurai; Katsuhiko Takayama; Hiroshi Yamaguchi; Hisao Maeda
Purpose: As part of a presurgical extracranial study, we performed intracranial electroencephalographic (EEG) recording by using micro‐guidewires as active intravascular electrodes in two patients with temporal lobe epilepsy in combination with the Wada test. In one case, there was good agreement among information derived from the non‐invasive assessments, such as ictal semiology, interictal and ictal data from long‐term EEG and video monitoring, magnetic resonance imaging (MRI) findings, single photon emission computed tomography (SPECT) findings, and neuropsychological studies, that consistently pointed to one temporal lobe as the epileptogenic region. The other case showed no definite information about the laterality of the epileptogenic region. The interictal scalp EEG for the two cases showed independent, bilateral, anterior to midtemporal spike foci. The ictal EEGs with sphenoidal electrodes showed no apparent changes initially and during simple partial seizures.
Psychiatry and Clinical Neurosciences | 2015
Yushi Inoue; Kazuichi Yagi; Akio Ikeda; Mutsuo Sasagawa; Shigenobu Ishida; Atsushi Suzuki; Katsumi Yoshida
The aim of this study was to confirm the efficacy and safety of adjunctive levetiracetam in adult Japanese patients with uncontrolled partial‐onset seizures.
Annals of General Hospital Psychiatry | 2004
Hiroto Ito; Toshiaki Kono; Shigenobu Ishida; Hisao Maeda
BackgroundWe examined gender difference in QTc interval distribution and its related factors in people with mental disorders.MethodsWe retrospectively reviewed medical charts of patients discharged from a university psychiatric unit between November 1997 and December 2000. Subjects were 328 patients (145 males and 183 females) taking psychotropics at their admission. We examined patient characteristics, medical history, diagnosis, and medication before admission.ResultsMean QTc interval was 0.408 (SD = 0.036). QTc intervals in females were significantly longer than those in males. QTc of females without comorbidity was significantly longer than that of males.ConclusionThe influence of gender difference on QTc prolongation in people with mental disorders merits further research.
Human Psychopharmacology-clinical and Experimental | 1997
Jun Nakamura; Naohisa Uchimura; Shigeto Yamada; Hisao Maeda; Shigenobu Ishida; Satoshi Tsuchiya; Takashi Hirano; Hiroki Ishii; Katsuhiko Takayama; Tsuyoshi Kotorii
Mianserin suppositories (10–90 mg) were administered at bedtime to 16 patients with post‐operative delirium (mean age 69·5 years). By the Delirium Rating Scale (DRS: Trzepacz et al., 1988), the average score decreased from 21·2 prior to administration to 14·5 on the first day of treatment and to 7·1 on the seventh day. Improvement was observed in all cases (marked in 85 per cent and slight in 15 per cent). The plasma concentration of mianserin was 65 ng/ml on day 1, 93 ng/ml on day 3 and 65 ng/ml on day 5, having reached therapeutic levels within 24 h of beginning treatment. Decreases in the free‐3‐methoxy‐4‐hydroxyphenyl(ethylene)glycol (MHPG) concentrations in plasma were observed after drug administration, but free‐homovanillic acid (HVA) concentrations in plasma showed no significant change with the drug treatment. We consider mianserin suppositories to be an effective treatment for post‐operative delirium.
Psychiatry and Clinical Neurosciences | 1995
Yoichi Nakazawa; Shigenobu Ishida; Hisao Maeda; Seishi Sakurai; Hiromichi Motooka
Abstract Antiepileptic drugs (AED) were discontinued in 55 epileptics who had been free from seizures treated with AED, in accordance with the following criteria and procedures. (i) A reduction in AED commences when patients have been free from seizures for at least 2 years and epileptic discharges have also disappeared in repeated electroencephalogram (EEG) recordings during that period. (ii) AED are gradually reduced if no relapse is seen in clinical seizures and epileptic discharges in EEG. (iii) As a rule at least 2 years are required as the interval from the onset of a reduction to the withdrawal of AED. Forty‐three patients were followed up by a questionnaire and/or by telephone and the follow‐up period from the withdrawal of AED to the survey ranged from 0.9 to 8.8 years; in 38 patients (88.4%) the period was longer than 2 years. No relapse of seizures was found in any of the 43 patients. The severity of epilepsy judged by the total number and frequency of seizures, the presence of neuropsychiatric complications, the combination of different types of seizures, and the duration of epilepsy from the seizure onset to the last seizure appeared not to be risk factors for the recurrence of seizure. Normal EEG was, however, considered to be an important prerequisite for a good prognosis.
JAMA Neurology | 2018
Taisei Mushiroda; Yukitoshi Takahashi; Teiichi Onuma; Yoshiaki Yamamoto; Tetsumasa Kamei; Tohru Hoshida; Katsuya Takeuchi; Kotaro Otsuka; Mitsutoshi Okazaki; Masako Watanabe; Kosuke Kanemoto; Tomohiro Oshima; Atsushi Watanabe; Shiro Minami; Kayoko Saito; Hisashi Tanii; Yasushi Shimo; Minoru Hara; Shinji Saitoh; Toshihiko Kinoshita; Masaki Kato; Naoto Yamada; Naoki Akamatsu; Toshihiko Fukuchi; Shigenobu Ishida; Shingo Yasumoto; Atsushi Takahashi; Takahisa Furuta; Yoshiro Saito; Nobuyuki Izumida
Importance Carbamazepine, a commonly used antiepileptic drug, is one of the most common causes of cutaneous adverse drug reactions (cADRs) worldwide. The allele HLA-A*31:01 is reportedly associated with carbamazepine-induced cADRs in Japanese and European populations; however, the clinical utility of HLA-A*31:01 has not been evaluated. Objective To assess the use of HLA-A*31:01 genetic screening to identify Japanese individuals at risk of carbamazepine-induced cADRs. Design, Setting, and Participants This cohort study was conducted across 36 hospitals in Japan from January 2012 to November 2014 among 1202 patients who had been deemed suitable to start treatment with carbamazepine. Preemptive HLA-A*31:01 genetic screening was performed for 1187 participants. Patients who did not start treatment with carbamazepine or alternative drugs were excluded. Participants were interviewed once weekly for 8 weeks to monitor the development of cADRs. Data analysis was performed from June 8, 2015, to December 27, 2016. Exposures Neuropsychiatrists were asked to prescribe carbamazepine for patients who tested negative for HLA-A*31:01 and alternative drugs for those who tested positive for HLA-A*31:01. Main Outcomes and Measures Incidence of carbamazepine-induced cADRs. Results Of the 1130 included patients who were prescribed carbamazepine or alternative drugs, the mean (range) age was 37.4 (0-95) years, 614 (54.3%) were men, and 198 (17.5%) were positive for HLA-A*31:01. Expert dermatologists identified 23 patients (2.0%) who had carbamazepine-induced cADRs, of which 4 patients required hospitalization. Drug-induced hypersensitivity syndrome was observed for 3 patients, maculopapular eruption for 9 patients, erythema multiforme for 5 patients, and an undetermined type of cADR for 6 patients. No patient developed Stevens-Johnson syndrome or toxic epidermal necrolysis. Compared with historical controls, the incidence of carbamazepine-induced cADRs was significantly decreased (for BioBank Japan data: incidence, 3.4%; odds ratio, 0.60; 95% CI, 0.36-1.00; P = .048; for the Japan Medical Data Centre claims database: incidence, 5.1%; odds ratio, 0.39; 95% CI, 0.26-0.59; P < .001). Conclusions and Relevance Preemptive HLA-A*31:01 genetic screening significantly decreased the incidence of carbamazepine-induced cADRs among Japanese patients, which suggests that it may be warranted in routine clinical practice.
Journal of The Japan Epilepsy Society | 1991
Takashi Renri; Seiichiroh Ueda; Takehiko Anraku; Shigenobu Ishida; Hiromi Satoh; Shusaku Tsujimaru; Yoichi Nakazawa; Jiroh Ueda
われわれは同一精薄施設の長期入所者87例 (うち62例はAED服用群) を対象と, て, 抗てんかん薬 (AED) と骨萎縮性病変の発生状況および, 1α-OH-D3 (VD) の骨萎縮性病変に対する効果について, MD法, MD/MS法を用いて3年間の追跡調査を行い, 以下の結果を得た。初回 (1986年) のMD法で正常であった57例は, VDを投与しなかったところ, 徐々にMD法で異常が出現し悪化した。なかでもAED服用群 (42例) に悪化傾向が強かった。初回のMD法で異常を認めた30例は, VDを投与したところ, 骨皮質の骨塩量 (GS max) の増加を主体に改善傾向を示し, 3年間投与, てもVDの効果の減弱や1副作用は認められなかった。なかでもAED服用群 (20例) の方が未服用群 (10例) よりも平均骨塩量 (ΣGS/D) と断面2次モーメント (I) が増加した。以上のことから, 特にAEDの投与中に認められた骨萎縮性病変には, VDの投与が有効であった。今回の対象とした精薄施設の入所者は全体的に特異なレーダーチャートを示したが, それは主に骨の横径発達の遅滞に関連, ていると思われた。
Neurologia Medico-chirurgica | 2009
Shintaro Fukushima; Masaru Hirohata; Yuji Okamoto; Shin Yamashita; Shigenobu Ishida; Minoru Shigemori
Annals of Neurology | 1998
Yushiro Yamashita; Toyojiro Matsuishi; Shigenobu Ishida; Toshihiro Nishimi; Hirohisa Kato